Vaccination Against SARS-Cov-2 among Patients with Parkinson’s Disease Based on the Results of COVPARK-LT Study
Background. COVID-19 in patients with Parkinson’s disease leads to worsening of symptoms and development of severe/critical conditions; its long-term consequences are still being investigated. Data on vaccination against SARS-Cov-2 in Parkinson’s disease are inconsistent. There are no publications o...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Vilnius University Press
2024-02-01
|
| Series: | Neurologijos seminarai |
| Subjects: | |
| Online Access: | https://www.journals.vu.lt/neurologijos_seminarai/article/view/34584 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593129897721856 |
|---|---|
| author | R. Kaladytė Lokominienė G. Lokominaitė |
| author_facet | R. Kaladytė Lokominienė G. Lokominaitė |
| author_sort | R. Kaladytė Lokominienė |
| collection | DOAJ |
| description | Background. COVID-19 in patients with Parkinson’s disease leads to worsening of symptoms and development of severe/critical conditions; its long-term consequences are still being investigated. Data on vaccination against SARS-Cov-2 in Parkinson’s disease are inconsistent. There are no publications on this topic regarding Lithuania.
Materials and methods. The retrospective study COVPARK-LT was performed in the Vilnius University Hospital Santaros Clinics in 2022. Methods: analysis of anonymous data from electronic patient histories obtained during consultations for Parkinson’s disease in the out-patient department (form E025).
Objective: To investigate COVID-19 vaccination status and associated factors in patients with Parkinson’s disease.
Results. 173 patients were enrolled, 68 males (39.3%) and 105 females (60.7%), the average age of the cohort was 67.99±1.34 years, the duration of Parkinson’s disease was 7.73±0.54 years. The rate of vaccination against SARS-Cov-2 with at least one dose was 85.6% among study patients and 69.8% in the general population. The rate of full vaccination against SARS-Cov-2 was 81.5% in COVPARK-LT and 33.4% in the general population. The rate of laboratory-proven COVID-19 was 20% (N=5) in the non-vaccinated group of the cohort and 22.3% (N=33) in the vaccinated group (p=0.087). COVID-19 vaccine-negativity was associated with the history of vaccination against non-SARS-Cov-2 infections (odds ratio, OR: 0.18, p < 0.01), vaccination against influenza (OR: 0.21, p<0.01), male gender (OR: 0.68, p<0.05), male age (OR: 0.88, p<0.05), duration of Parkinson’s disease (OR: 1.1, p<0.001), and Parkinson’s disease stage according to Hoehn-Yahr (OR: 0.51, p<0.05).
Conclusions. The rate of vaccination against SARS-Cov-2 was higher in the COVPARK-LT cohort patients than in the general population in Lithuania. Non-vaccinated status was positively associated with female gender, younger age in men and earlier stage of Parkinson’s disease according to Hoehn-Yahr staging. Vaccinated status was associated with vaccination against other infectious diseases (influenza, tick-borne encephalitis, pneumococcus). The rate of COVID-19 in the COVPARK-LT cohort did not differ between non-vaccinated and vaccinated patients with Parkinson’s disease.
|
| format | Article |
| id | doaj-art-ed5d474caf0e4dfaa9283dfe23fa3491 |
| institution | Kabale University |
| issn | 1392-3064 2424-5917 |
| language | English |
| publishDate | 2024-02-01 |
| publisher | Vilnius University Press |
| record_format | Article |
| series | Neurologijos seminarai |
| spelling | doaj-art-ed5d474caf0e4dfaa9283dfe23fa34912025-01-20T18:21:57ZengVilnius University PressNeurologijos seminarai1392-30642424-59172024-02-0127No. 2 (96)10.29014/NS.2023.27.12Vaccination Against SARS-Cov-2 among Patients with Parkinson’s Disease Based on the Results of COVPARK-LT StudyR. Kaladytė Lokominienė0G. Lokominaitė1Vilnius University, LithuaniaVilnius University, LithuaniaBackground. COVID-19 in patients with Parkinson’s disease leads to worsening of symptoms and development of severe/critical conditions; its long-term consequences are still being investigated. Data on vaccination against SARS-Cov-2 in Parkinson’s disease are inconsistent. There are no publications on this topic regarding Lithuania. Materials and methods. The retrospective study COVPARK-LT was performed in the Vilnius University Hospital Santaros Clinics in 2022. Methods: analysis of anonymous data from electronic patient histories obtained during consultations for Parkinson’s disease in the out-patient department (form E025). Objective: To investigate COVID-19 vaccination status and associated factors in patients with Parkinson’s disease. Results. 173 patients were enrolled, 68 males (39.3%) and 105 females (60.7%), the average age of the cohort was 67.99±1.34 years, the duration of Parkinson’s disease was 7.73±0.54 years. The rate of vaccination against SARS-Cov-2 with at least one dose was 85.6% among study patients and 69.8% in the general population. The rate of full vaccination against SARS-Cov-2 was 81.5% in COVPARK-LT and 33.4% in the general population. The rate of laboratory-proven COVID-19 was 20% (N=5) in the non-vaccinated group of the cohort and 22.3% (N=33) in the vaccinated group (p=0.087). COVID-19 vaccine-negativity was associated with the history of vaccination against non-SARS-Cov-2 infections (odds ratio, OR: 0.18, p < 0.01), vaccination against influenza (OR: 0.21, p<0.01), male gender (OR: 0.68, p<0.05), male age (OR: 0.88, p<0.05), duration of Parkinson’s disease (OR: 1.1, p<0.001), and Parkinson’s disease stage according to Hoehn-Yahr (OR: 0.51, p<0.05). Conclusions. The rate of vaccination against SARS-Cov-2 was higher in the COVPARK-LT cohort patients than in the general population in Lithuania. Non-vaccinated status was positively associated with female gender, younger age in men and earlier stage of Parkinson’s disease according to Hoehn-Yahr staging. Vaccinated status was associated with vaccination against other infectious diseases (influenza, tick-borne encephalitis, pneumococcus). The rate of COVID-19 in the COVPARK-LT cohort did not differ between non-vaccinated and vaccinated patients with Parkinson’s disease. https://www.journals.vu.lt/neurologijos_seminarai/article/view/34584Parkinson’s diseaseCOVID-19SARS-CoV-2vaccination |
| spellingShingle | R. Kaladytė Lokominienė G. Lokominaitė Vaccination Against SARS-Cov-2 among Patients with Parkinson’s Disease Based on the Results of COVPARK-LT Study Neurologijos seminarai Parkinson’s disease COVID-19 SARS-CoV-2 vaccination |
| title | Vaccination Against SARS-Cov-2 among Patients with Parkinson’s Disease Based on the Results of COVPARK-LT Study |
| title_full | Vaccination Against SARS-Cov-2 among Patients with Parkinson’s Disease Based on the Results of COVPARK-LT Study |
| title_fullStr | Vaccination Against SARS-Cov-2 among Patients with Parkinson’s Disease Based on the Results of COVPARK-LT Study |
| title_full_unstemmed | Vaccination Against SARS-Cov-2 among Patients with Parkinson’s Disease Based on the Results of COVPARK-LT Study |
| title_short | Vaccination Against SARS-Cov-2 among Patients with Parkinson’s Disease Based on the Results of COVPARK-LT Study |
| title_sort | vaccination against sars cov 2 among patients with parkinson s disease based on the results of covpark lt study |
| topic | Parkinson’s disease COVID-19 SARS-CoV-2 vaccination |
| url | https://www.journals.vu.lt/neurologijos_seminarai/article/view/34584 |
| work_keys_str_mv | AT rkaladytelokominiene vaccinationagainstsarscov2amongpatientswithparkinsonsdiseasebasedontheresultsofcovparkltstudy AT glokominaite vaccinationagainstsarscov2amongpatientswithparkinsonsdiseasebasedontheresultsofcovparkltstudy |